Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC
He describes the rationale for PLK1 inhibition and highlights the significance of the data, which will have an additional update next year. Plus, where Cardiff believes it can go beyond colorectal cancer with this asset.